tbuckley/cabot-search huggingface dataset:
Over-the-counter Cold Medications
Authors: Michael B. H. Smith
Journal: JAMA (1993)

<h3>Objective.</h3> —To determine whether over-the-counter cold medications have been shown to be effective in relieving symptoms in children, adolescents, and adults. <h3>Data Sources.</h3> —The MEDLINE database using the key words combined with medications and research and review articles. Articles were retrieved if they were written in English and published between January 1950 and January 1991. <h3>Study Selection.</h3> —Articles were selected if they described a controlled clinical trial on the treatment of the common cold. Forty-eight percent of 106 articles met the selection criteria, and these were grouped by age into child studies (&lt;5 years old and &lt;12 years old) and adolescent (aged 12 years and older)/adult studies. <h3>Data Extraction.</h3> —Each article was scored on 11 criteria to determine scientific validity. Those articles scoring above 70% were included in the final analysis. Two authors independently scored a sample of articles to determine interrater reliability. <h3>Data Synthesis.</h3> —Very few studies have been performed on children. Of those, two done on preschool children demonstrated no symptom relief, whereas two done on older children showed some benefit. In the adolescent/adult studies, chlorpheniramine maleate, pseudoephedrine hydrochloride, oxymetazoline hydrochloride, phenylpropanolamine hydrochloride, ipratropium bromide, and atropine methonitrate all improved nasal symptoms. Combination therapy (using an antihistamine-decongestant mix) was shown to relieve a variety of symptoms. <h3>Conclusions.</h3> —No good evidence has demonstrated the effectiveness of over-the-counter cold medications in preschool children. Furthur studies are required to clarify the role of these medications in children. Certain single over-the-counter medications and combinations have been shown to reduce cold symptoms in adolescents and adults. (<i>JAMA</i>. 1993;269:2258-2263)
Questions and Answers
Authors: Owen Belmont
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Darier Disease
Authors: Abraham M. Korman, Nima Milani-Nejad
Journal: JAMA Dermatology (2020)

This case report describes a patient with pruritic rash, white and red streaks and V-shaped notching of the fingernails, yellow-brown greasy papules on the thighs and chest, and small white papules on the oral gingivae coalescing into cobblestoned plaques.
Two fatalities after acute occupational exposure to ethylene dibromide
Authors: G. A. Letz
Journal: JAMA (1984)

A worker collapsed while working inside a tank that was later found to contain residues of ethylene dibromide. He died 12 hours later with metabolic acidosis, depression of the CNS, and laboratory evidence of liver damage. A supervisor attempting to rescue the first victim also collapsed inside the tank and died 64 hours later with intractable metabolic acidosis and hepatic and renal failure. The clinical, pathological, and toxicological findings, as well as results of industrial hygiene sampling, are reported. Pathophysiological mechanisms and possible therapeutic interventions are discussed. The cases demonstrate the extreme hazards of exposure to the highly toxic chemical. The importance of protective work practices wherever there is potential exposure to ethylene dibromide is emphasized. (<i>JAMA</i>1984;252:2428-2431)
Seasonal distribution in conceptions achieved by artificial insemination by donor.
Journal: BMJ (1989)

patients with confirmed acute myocardial infarc- tion were admitted to the seven bedded coronary care unit of Leicester Royal Infirmary within six hours after the onset of symptoms.Thrombolytic treatment of that number of patients would cost £29 000 with streptokinase compared with £344 000 with plasminogen activator for the drugs alone, according to the manufacturers' published prices.Streptokinase (plus aspirin) will remain the best treatment until evidence from direct comparative trials shows that an alternative thrombolytic agent can result in a lower mortality or until the price of an equally effective drug becomes competitive.
DERMATOSES AND ULTRAVIOLET IRRADIATION
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Occult temporal arteritis
Authors: J. A. Gutrecht
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of estrogens on sleep and psychological state of hypogonadal women
Authors: I. Schiff
Journal: JAMA (1979)

A double-blind crossover study involving 16 hypogonadal women compared the effects of placebo and cunjugated estrogens, 0.625 mg daily, on gonadotropin levels, symptoms, sleep patterns, and psychological state. After one month, serum concentrations of follicle-stimulating hormone fell 31%, and levels of luteinizing hormone, 19%; the number of vasomotor flushes also decreased. The administration of estrogens was also associated with a shorter mean sleep latency, a longer period of rapid eye movement sleep, and a positive correlation between psychological intactness (as clinically ranked) and latency to sleep onset. Psychological testing, including the Clyde Mood Scale, and the Gottschalk-Gleser Test indicated that estrogens caused this group to be less outwardly aggressive but more inwardly hostile. (<i>JAMA</i>242:2405-2407, 1979)
AMBIDEXTERITY.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.
Authors: Anne Patsouris, Olivier Tredan, Loic Campion, Anthony Goncalves, Monica Arnedos, Marie Paule Sablin, Pascal Jézéquel, Marta Jimenez, Veronica Pezzella, Ivan Bieche, Celine Callens, Andrea Loehr, Daniel Nenciu, Cecile Vicier, Fabrice Andre
Journal: Journal of Clinical Oncology (2018)

TPS1112 Background: Rucaparib, a potent oral PARP-1, -2 and -3 inhibitor, has shown activity in a phase 3 study in patients (pts) with ovarian carcinoma (ARIEL 3) harbouring a BRCA mutation or an homologous recombination deficient (HRD) profile defined by high percentage of genome-wide loss of heterozygosity and in a phase 1 study that included breast cancer pts with germline BRCA mutation (Kristeleit et al, Clin Can Res, 2017). High genomic LOH score identified HRD tumors (also known as BRCAness tumors), including both known BRCA1 methylation and unknown genetic/epigenetic mechanisms and somatic BRCA1/2 mutations. This single arm, open-label, multicenter phase II RUBY study (NCT02505048) is evaluating the efficacy and safety of rucaparib in pts with HER2- metastatic breast cancer (MBC) associated with a "high tumor genomic LOH" score and/or a somatic BRCA mutation (excluding BRCA1 and/or BRCA2 germline mutation). Methods: Women with HER2- MBC with a HRD phenotype who received at least 1 prior chemotherapy regimens are eligible. ECOG PS 0-1 and adequate organ function is required. HRD phenotype is defined by a "high tumor genomic LOH" score, generated from the CytoScan HD SNP array, which is available from the SAFIR02 (NCT02299999) or SAFIR-TOR (NCT02444390) protocols. Pts received oral rucaparib 600 mg BID continuously in 21-day cycles until disease progression. The primary endpoint is clinical benefit rate (CBR), defined by complete and partial response and stable disease lasting for at least 16 weeks. If CBR is significant the objective response rate (ORR) will be considered as well. Secondary endpoints include progression-free survival, overall survival, safety, and the prognostic value of the HRD signature. This trial design is intended to establish proof-of-concept that rucaparib can improve ORR in HER2- MBC with HRD. Targeted enrollment is 41 pts using a Simon two-stage design, 19 pts in the first step and 22 pts in the second one. The prespecified goal of the first step was achieved; enrollment into the second step is ongoing. Clinical trial information: NCT02505048.
Williams Obstetrics
Authors: Bernard A. Eskin
Journal: JAMA (1994)

This classic textbook has been generously reworked and extensively enlarged by the obstetric group at Parkland Hospital (Dallas, Tex) and remains an excellent source book with competent authors and prudent references. When I compared a much earlier edition with this, I was moved by the impressive changes and advances in obstetrics over the years. However, I disagree with the statement in the preface that the earnest effort to achieve scientific approaches to obstetrics began only with the perinatal subspecialty in 1960. The exponential advances seen in all medical disciplines, including our own specialty, are founded on previous extensive study of basic physiology. This textbook now includes five authorities who provide commentary and approaches other than those used exclusively at the Parkland Hospital, thus coping with a serious criticism of former editions written by this group. This commitment expands the depth of the practice and art of the specialty and adds
THE SESQUICENTENNIAL OF THE HYDROGEN BALLOON
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gesetz zur Verhütung erbkranken Nachwuchses vom 14. Juli 1933 mit Auszug aus dem Gesetz gegen gefährliche Gewohnheitsverbrecher und über Maszregeln der Sicherung und Besserung vom 24. Nov. 1933
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Death caused by fermenting manure
Authors: D. L. Morse
Journal: JAMA (1981)

FARM workers are at risk of contracting a unique set of occupationally related illnesses.<sup>2,3</sup>Chemical toxicity is usually pesticide related but is also seen in settings like silage storage where toxic gases can be released. In contrast, manure handling has involved little chemical exposure except for that experienced through the nasal route. We present information to document how conversion of waste management units to more efficient liquid-manure systems can result in an increased risk of toxic chemical exposure. <h3>Report of a Case</h3> A 16-year-old farm worker began using high-pressure hot water to clean manure from gutters inside a recently emptied calf barn in Wisconsin. He was 10 m from a 378,500-L underground liquid-manure storage tank, the contents of which had been agitating for 30 to 60 minutes (Figure). After ten minutes he began to cough, vomited, collapsed, and died. A co-worker who was working close to an exhaust fan
Pulmonary vasculitis
Authors: A. Burns
Journal: Thorax (1998)

<h3>Abstract</h3> <h3>Objective</h3> Despite the importance of social cognitive functions to mental health and social adjustment, assessment of these functions is absent in routine assessment of epilepsy patients. Thus, this review aims to provide a comprehensive overview of the literature on four major aspects of social cognition among temporal and frontal lobe epilepsy, which is a critical step towards designing new interventions. <h3>Method</h3> Papers from 1990-2021 were reviewed and examined for inclusion in this study. After the deduplication process, a systematic review and meta-analysis of 44 and 40 articles, respectively, involving 113 people with frontal lobe epilepsy and 1482 people with temporal lobe epilepsy were conducted. <h3>Results</h3> Our results indicated that while patients with frontal or temporal lobe epilepsy have difficulties in all aspects of social cognition relative to non-clinical controls, the effect sizes were larger for theory of mind (<i>g</i>= 0.95), than for emotion recognition (<i>g</i>=0.69) among temporal lobe epilepsy group. The frontal lobe epilepsy group exhibited significantly greater impairment in emotion recognition compared to temporal lobe. Additionally, people with right temporal lobe epilepsy (<i>g</i>= 1.10) performed more poorly than those with a left-sided (<i>g</i>= 0.90) seizure focus, specifically in the theory of mind domain. <h3>Conclusions</h3> These data point to a potentially important difference in the severity of deficits within the emotion recognition and theory of mind abilities depending on the laterlization of seizure side. We also suggest a guide for the assessment of impairments in social cognition that can be integrated into multidisciplinary clinical evaluation for people with epilepsy
THE PREFERRED BASE FOR ZINC OXID OINTMENT
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Expression of mucin core protein of mammary type in primary liver cancer
Authors: M Sasaki
Journal: Hepatology (1994)

Expression of mucin core protein of mammary type (MUC-1 core protein) was investigated in primary hepatic carcinoma (25 cases of cholangiocarcinoma, 15 cases of combined hepatocellular-cholangiocellular carcinoma and 18 cases of hepatocellular carcinoma) with monoclonal antibody DF3 and a standard avidinbiotin complex method. MUC-1 core protein was almost always expressed in cholangiocarcinoma and in the cholangiocarcinoma area of hepatocellular-cholangiocellular carcinoma to a varied degree, whereas such expression was virtually absent in hepatocellular carcinoma and the hepatocellular carcinoma areas of hepatocellular-cholangiocellular carcinoma. Nonneoplastic intrahepatic biliary epithelium, as well as hepatocytes, was virtually negative for this protein. In well-differentiated cholangiocarcinoma, this protein tended to be expressed on luminal surfaces, whereas poorly differentiated cholangiocarcinoma showed cell membranous or diffuse cytoplasmic staining patterns. Double staining with Alcian blue (pH 2.5) and immunostaining for MUC-1 core protein showed that although some parts of cancerous areas were positive for both stains, most cancerous areas were only positive for one. Alcian blue—positive areas were dominant over MUC-1 core protein—expressing areas in well-differentiated cholangiocarcinoma, whereas the reverse was the case in poorly differentiated cholangiocarcinomas and also in cholangiocarcinoma areas of hepatocellular-cholangiocellular carcinoma. This study is the first report to document that cholangiocarcinoma and cholangiocarcinoma areas of hepatocellular-cholangiocellular carcinoma express MUC-1 core protein. In addition, MUC-1 core protein—expressing areas and Alcian blue—positive areas in cholangiocarcinoma and cholangiocarcinoma areas of hepatocellular-cholangiocellular carcinoma were reciprocally distributed in most cancerous areas, suggesting that immunostaining for MUC-1 core protein can be used to supplement conventional mucin histochemical study in cholangiocarcinoma and hepatocellular-cholangiocellular carcinoma. (Hepatology 1994;20:1192–1197).
Resident Forum
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal